|
1
|
Conforti A, Di Cola I, Pavlych V, Ruscitti
P, Berardicurti O, Ursini F, Giacomelli R and Cipriani P: Beyond
the joints, the extra-articular manifestations in rheumatoid
arthritis. Autoimmun Rev. 20(102735)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Dadoun S, Zeboulon-Ktorza N, Combescure C,
Elhai M, Rozenberg S, Gossec L and Fautrel B: Mortality in
rheumatoid arthritis over the last fifty years: Systematic review
and meta-analysis. Joint Bone Spine. 80:29–33. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
England BR, Thiele GM, Anderson DR and
Mikuls TR: Increased cardiovascular risk in rheumatoid arthritis:
Mechanisms and implications. BMJ. 361(k1036)2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Smolen JS: Insights into the treatment of
rheumatoid arthritis: A paradigm in medicine. J Autoimmun.
110(102425)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Brennan FM and McInnes IB: Evidence that
cytokines play a role in rheumatoid arthritis. J Clin Invest.
118:3537–3545. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Meng X, Al-Attar Z, Yaseen FS, Jenkins R,
Earnshaw C, Whitaker P, Peckham D, French NS, Naisbitt DJ and Park
BK: Definition of the nature and hapten threshold of the β-lactam
antigen required for T cell activation in vitro and in patients. J
Immunol. 198:4217–4227. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gibson A, Faulkner L, Lichtenfels M, Ogese
M, Al-Attar Z, Alfirevic A, Esser PR, Martin SF, Pirmohamed M, Park
BK and Naisbitt DJ: The effect of inhibitory signals on the priming
of drug hapten-specific T cells that express distinct Vβ receptors.
J Immunol. 199:1223–1237. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Al-Saraj M, Al-Ethary Z and Al-Attar Z:
The effect of low level laser therapy on early onset rheumatoid
arthritis patients. Iraqi J Med Sci. 19:126–133. 2021.
|
|
9
|
Zhao S, Wu B and Stevens RC: Advancing
chemokine GPCR structure based drug discovery. Structure.
27:405–408. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wasilko DJ, Johnson ZL, Ammirati M, Che Y,
Griffor MC, Han S and Wu H: Structural basis for chemokine receptor
CCR6 activation by the endogenous protein ligand CCL20. Nat Commun.
11(3031)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Abdulla WL, A-Ghurabi BH and Gathwan KH:
An impairment of salivary gland function in rheumatoid arthritis:
Association with change in salivary biomarkers and disease
activity. J Bagh Coll Dent. 28:165–170. 2016.
|
|
12
|
Ranasinghe R and Eri R: Modulation of the
CCR6-CCL20 axis: A potential therapeutic target in inflammation and
cancer. Medicina (Kaunas). 54(88)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lee AYS and Körner H: The CCR6-CCL20 axis
in humoral immunity and T-B cell immunobiology. Immunobiology.
224:449–454. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Aldhaher Z, Al-Ghurabi B and Alwan B:
Serum levels of IL-22 and ACPA in patients with rheumatoid
arthritis. J Pure Appl Microbiol. 12:687–691. 2018.
|
|
15
|
Li H, Wu M and Zhao X: Role of chemokine
systems in cancer and inflammatory diseases. MedComm (2020).
3(e147)2022.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
Martina MG, Giorgio C, Allodi M, Palese S,
Barocelli E, Ballabeni V, Szpakowska M, Chevigné A, Piet van
Hamburg J, Davelaar N, et al: Discovery of small-molecules
targeting the CCL20/CCR6 axis as first-in-class inhibitors for
inflammatory bowel diseases. Eur J Med Chem.
243(114703)2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Meitei HT, Jadhav N and Lal G: CCR6-CCL20
axis as a therapeutic target for autoimmune diseases. Autoimmun
Rev. 20(102846)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Al Obaidi MJ and Al Ghurabi BH: Potential
role of NLRP3 inflammasome activation in the pathogenesis of
periodontitis patients with type 2 diabetes mellitus. J Med Chem
Sci. 6:522–531. 2023.
|
|
19
|
Mills KHG: IL-17 and IL-17-producing cells
in protection versus pathology. Nat Rev Immunol. 23:38–54.
2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hirota K, Yoshitomi H, Hashimoto M, Maeda
S, Teradaira S, Sugimoto N, Yamaguchi T, Nomura T, Ito H, Nakamura
T, et al: Preferential recruitment of CCR6-expressing Th17 cells to
inflamed joints via CCL20 in rheumatoid arthritis and its animal
model. J Exp Med. 204:2803–2812. 2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ciofani M, Madar A, Galan C, Sellars M,
Mace K, Pauli F, Agarwal A, Huang W, Parkhurst CN, Muratet M, et
al: A validated regulatory network for Th17 cell specification.
Cell. 151:289–303. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Buczko P, Zalewska A and Szarmach I:
Saliva and oxidative stress in oral cavity and in some systemic
disorders. J Physiol Pharmacol. 66:3–9. 2015.PubMed/NCBI
|
|
23
|
Finckh A, Gilbert B, Hodkinson B, Bae SC,
Thomas R, Deane KD, Alpizar-Rodriguez D and Lauper K: Global
epidemiology of rheumatoid arthritis. Nat Rev Rheumatol.
18:591–602. 2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Talib AF and Mohammed MM: Treatment
satisfaction and health-related quality of life in iraqi patients
with rheumatoid arthritis receiving biologic therapy; Rituximab.
Iraqi J Pharm Sci. 33 (4SI):230–235. 2024.
|
|
25
|
Bukhari M, Lunt M, Harrison BJ, Scott DGI,
Symmons DPM and Silman AJ: Rheumatoid factor is the major predictor
of increasing severity of radiographic erosions in rheumatoid
arthritis: Results from the norfolk arthritis register study, a
large inception cohort. Arthritis Rheum. 46:906–912.
2002.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hassoon HJ, Jasim WE and Abbas AAH: The
evaluation of some biomarkers according to rheumatoid factor in
early diagnosis of rheumatoid arthritis from Iraqi patients. Iraqi
J Sci. 61:2196–2203. 2020.
|
|
27
|
Khidhir RM and Al-Jubouri RH: The study of
tempromandibular joint disorders and anti-cyclic citrullinated
peptide antibodies in serum and saliva of patients with rheumatoid
arthrit. J Bagh Coll Dent. 25:67–71. 2013.
|
|
28
|
Jassim NAL, Ibrahim DH and Gorial FI:
Efficacy and safety of etanercept in severely active rheumatoid
arthritis: 6-Month, open label, prospective, observational study
from Iraq. Adv Life Sci Technol. 40:27–34. 2015.
|
|
29
|
Hemdan NYA, Birkenmeier G, Wichmann G,
El-Saad AMA, Krieger T, Conrad K and Sack U:
Interleukin-17-producing T helper cells in autoimmunity. Autoimmun
Rev. 9:785–792. 2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Atwa SE, Azab MM, Mohamed MS and El sheikh
MM: Serum interleukin-17 level in patients with rheumatoid
arthritis and its relation to disease activity. Zagazig Univ Med J.
26:87–93. 2020.
|
|
31
|
Moran EM, Mullan R, McCormick J, Connolly
M, Sullivan O, FitzGerald O, Bresnihan B, Veale DJ and Fearon U:
Human rheumatoid arthritis tissue production of IL-17A drives
matrix and cartilage degradation: synergy with tumour necrosis
factor-alpha, Oncostatin M and response to biologic therapies.
Arthritis Res Ther. 11(R113)2009.PubMed/NCBI View
Article : Google Scholar
|
|
32
|
Roşu A, Mărgăritescu C, Stepan A,
Muşetescu A and Ene M: IL-17 patterns in synovium, serum and
synovial fluid from treatment-naïve, early rheumatoid arthritis
patients. Rom J Morphol Embryol. 53:73–80. 2012.PubMed/NCBI
|
|
33
|
Lina C, Conghua W, Nan L and Ping Z:
Combined treatment of etanercept and MTX reverses Th1/Th2,
Th17/Treg imbalance in patients with rheumatoid arthritis. J Clin
Immunol. 31:596–605. 2011.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Cheng P, Zhang Y, Huang H, Zhang W, Yang
Q, Guo F and Chen A: Association between CCR6 and rheumatoid
arthritis: A meta-analysis. Int J Clin Exp Med. 8:5388–5396.
2015.PubMed/NCBI
|
|
35
|
Komatsu N and Takayanagi H: Regulatory T
cells in arthritis. Prog Mol Biol Transl Sci. 136:207–215.
2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Adams C, Nair N, Plant D, Verstappen SMM,
Quach HL, Quach DL, Carvidi A, Nititham J, Nakamura M, Graf J, et
al: Identification of cell-specific differential DNA methylation
associated with methotrexate treatment response in rheumatoid
arthritis. Arthritis Rheumatol. 75:1088–1097. 2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Schmalzing M, Behrens F, Schwaneck EC,
Koehm M, Greger G, Gnann H, Burkhardt H and Tony HP: Does
concomitant methotrexate confer clinical benefits in patients
treated with prior biologic therapy? Analysis of data from a
noninterventional study of rheumatoid arthritis patients initiating
treatment with adalimumab. Medicine (Baltimore).
99(e20201)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Bonelli M, Puchner A, Göschl L, Hayer S,
Niederreiter B, Steiner G, Tillmann K, Plasenzotti R, Podesser B,
Georgel P, et al: CCR6 controls autoimmune but not innate
immunity-driven experimental arthritis. J Cell Mol Med.
22:5278–5285. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Crijns H, Vanheule V and Proost P:
Targeting chemokine-glycosaminoglycan interactions to inhibit
inflammation. Front Immunol. 11(483)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Lee AYS and Körner H: CCR6 and CCL20:
Emerging players in the pathogenesis of rheumatoid arthritis.
Immunol Cell Biol. 92:354–358. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Rampersad RR, Tarrant TK, Vallanat CT,
Quintero-Matthews T, Weeks MF, Esserman DA, Clark J, Di Padova F,
Patel DD, Fong AM and Liu P: Enhanced Th17-cell responses render
CCR2-deficient mice more susceptible for autoimmune arthritis. PLoS
One. 6(e25833)2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Sikorska D, Rutkowski R, Łuczak J,
Samborski W and Witowski J: No effect of anti-TNF-α treatment on
serum IL-17 in patients with rheumatoid arthritis. Cent Eur J
Immunol. 43:270–275. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Elemam NM, Hannawi S and Maghazachi AA:
Role of chemokines and chemokine receptors in rheumatoid arthritis.
Immunotargets Ther. 9:43–56. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Miyabe Y, Miyabe C, Iwai Y and Luster AD:
Targeting the chemokine system in rheumatoid arthritis and
vasculitis. JMA J. 3:182–192. 2020.PubMed/NCBI View Article : Google Scholar
|
